NSABP FC6: A Phase II Study to Determine the Surgical Conversion Rate in Patients receiving Neoadjuvant mFOLFOX7 Plus Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer with Metastases Confined to the Liver
Aims: The main purpose of this study is to determine if adding the drug cetuximab to standard chemotherapy will shrink the tumor(s) in your liver enough to allow the remaining tumor(s) to be removed by surgery. This study’s treatment plan is the same as the standard of care for your disease; however, you will be monitored more closely with scans to ensure that your surgery is performed as soon as your tumor shrinks. In addition, you will be getting medicine to help lessen the side effects of the chemotherapy. The risks of this study are similar to those that you would experience even if you were not participating in this study.
Diagnosis: Wild-Type K-RAS Colorectal Cancer with Liver Metastases
Principal Investigator: Jennifer Obel, MD
IRB Approval Number: EH10-309
Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Aims: This study is being done to evaluate the effects (good and bad) of different chemotherapy drugs. One of the common combinations of chemotherapy drugs used to treat your type of cancer is called “FOLFOX" and includes the drugs 5-fluorouracil (also called 5-FU), leucovorin and oxaliplatin. In this study, we will evaluate the effects (good and bad) of an oral drug called celecoxib when given in combination with FOLFOX chemotherapy. Celecoxib is approved by the FDA to treat arthritis and to help prevent colon polyps in people with a genetic risk for colon cancer.
Diagnosis: Stage III Colon Cancer
Principal Investigator: Jennifer Obel, MD
IRB Approval Number: EH11-055
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes 

Z6051: A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resection Versus Open Resection for Rectal Cancer
Aims: The purpose of this study is to compare two types of surgery currently used for rectal cancer.The two types of surgery to remove part of the rectum (resection) are laparoscopic-assisted surgery, which is performed through small incisions in the abdomen with use of special equipment, or open surgery, where a larger incision is made into the abdomen.
Diagnosis: Rectal Cancer
Principal Investigator: Marc Singer, MD
IRB Approval Number: EH10-333
Sponsor: American College of Surgeons Oncology Group (ACOSOG)
Contact: Interested patients should contact study coordinator Karen Ohara at 847-570-1572
Open to Enrollment: Yes

NLG-0405: A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute® Pancreatic Cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer
Aims: The purpose of this study is to find a new way to make the immune system recognize pancreatic cancer and encourage it to attack the cancer cells. The trial involves a vaccination of laboratory-grown human pancreatic cancer cells that contain a specific mouse gene. The mouse genes allow these cancer cells to produce specific sugars on their cells surfaces. The human immune system recognizes these sugars as foreign and may mount an attack on these cancer cells.
Diagnosis: Pancreatic Cancer 
Principal Investigator: Jennifer Obel, MD
IRB Approval Number: EH10-246
Sponsor: New Link Genetics
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

EH12-267: A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Aims: The purpose of this study is to evaluate whether it is possible to give a combination of chemotherapy drugs known as mFOLFIRINOX (5FU, leucovorin irinotecan, and oxaliplatin) before and after surgery to remove pancreatic cancer. This combination of drugs is an established treatment for pancreatic cancer which has spread to other parts of the body and this study may determine whether using it much earlier in the treatment of this cancer is beneficial. A second purpose is to evaluate the effect this treatment has on pancreatic cancer and on participants' survival.  
Diagnosis: Localized, Resectable Pancreatic Adenocarcinoma 
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH12-267
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

LCCC 1029: A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer
Aims: The purpose of this study is to assess if the drug regorafenib, when given in combination with FOLFIRI chemotherapy, will result in increased survival as compared to a placebo given in combination with FOLFIRI. The placebo is a sugar pill which looks like the real regorafenib tablet but does not contain any active study drug.
Diagnosis: K-RAS or BRAF Mutant Metastatic Colorectal Cancer
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH12-041
Sponsor: Lineberger Comprehensive Cancer Center (LCCC)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
Aims: In this study, patients will get radiation and chemotherapy with or without the drug cetuximab. The purpose of this study is to compare the effects, good and/or bad, of radiation therapy and chemotherapy (paclitaxel and cisplatin) with or without the addition of cetuximab to find out which treatment is better. Cetuximab may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. Cetuximab is approved by the FDA for the treatment of colorectal and head and neck cancers but is investigational for esophageal cancer.  
Diagnosis: Esophageal Cancer 
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH09-179
Sponsor: Radiation Therapy Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

× Alternate Text